AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04728243 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: WHO COVID-19 online training
Description: The WHO novel coronavirus 2019 online training series provides a general introduction to COVID-19 and similar respiratory infections and information on what facilities and professionals should be doing to prevent and respond to COVID-19 cases. The training is similar in length to the WHO QualityRights training (13 h 15 min vs. 19 hours) and is intended for health professionals and other stakeholders.
Study NCT05427786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorandil
Description: Administer 8cc or more of the prescribed drug according to randomization into the coronary artery before starting balloon therapy. The stent treatment method follows the standard treatment method.
Study NCT05897099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Tele-harm Reduction
Description: Comprehensive Tele-Harm Reduction is on-demand services including low-barrier access to PrEP, medications for substance use disorder and hepatitis C treatment. It includes mobile phlebotomy, peer harm reduction counseling, medication management, telehealth mental health/substance use disorder services-- all delivered via an syringe services program.
Study NCT05897099 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Off-site Linkage to HIV Prevention
Description: The community engagement team is comprised of peers and social workers and provides the wraparound support needed.The team will assist participants in scheduling appointments at community health clinics. The community engagement team provides active clinic referral- that is, a member of the team will accompany patients to the first clinic visit.
Study NCT04709536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI306
Description: Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24
Study NCT04709536 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24
Study NCT05710068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF Microneedle
Description: Pulsed-type RF device in bipolar mode with 25 non-insulated microneedles every 2 weeks for 6 month
Study NCT05710068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination cream
Description: 5% hydroquinone, 0.003% tretinoin, and 1% hydrocortisone twice daily for 2 months
Study NCT05710068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination cream
Description: 5% hydroquinone, 0.003% tretinoin, and 1% hydrocortisone twice daily for 2 months
Study NCT05811338 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project 1, Phase 2: VR Program for Social, Activity, and Cognitive Engagement
Description: The investigators will apply a systematic approach to the design and evaluation of an immersive Cognitive Activity Social Technology (CAST) VR intervention (using the Oculus Quest 2), that provides aging adults a suite of virtual cognitive, social, and activity engagement applications. The program will allow for virtual interactions (one-on one or groups), cultural, creativity, and educational opportunities, and gaming.
Study NCT05811338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project 1, Phase 2: VR Program for Social, Activity, and Cognitive Engagement
Description: The investigators will apply a systematic approach to the design and evaluation of an immersive Cognitive Activity Social Technology (CAST) VR intervention (using the Oculus Quest 2), that provides aging adults a suite of virtual cognitive, social, and activity engagement applications. The program will allow for virtual interactions (one-on one or groups), cultural, creativity, and educational opportunities, and gaming.
Study NCT05811338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project 2, Phase 2: Intelligent Adaptive System
Description: An innovative intelligent adaptive software package aimed at providing social and cognitive support to older adults with MCI. The system will be designed to adapt to the needs and abilities of the user.
Study NCT05811338 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project 2, Phase 2: Intelligent Adaptive System
Description: An innovative intelligent adaptive software package aimed at providing social and cognitive support to older adults with MCI. The system will be designed to adapt to the needs and abilities of the user.
Study NCT05811338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project 3, Phase 3: Intelligent Decision Support Tool
Description: An innovative intelligent decision tool for health decisions aims at providing health management support for older adults with and without MCI.
Study NCT05811338 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project 3, Phase 3: Intelligent Decision Support Tool
Description: An innovative intelligent decision tool for health decisions aims at providing health management support for older adults with and without MCI.
Study NCT05780645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050 MR Prototype Tablet
Description: Participants will receive various doses of the MR Prototype Tablet orally.
Study NCT05780645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050 Immediate Release (IR) Tablet
Description: Participants will receive a single dose IR (ALXN2050 Film Coated Tablet) tablet orally.
Study NCT05780645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050 MR Prototype Mini-Tablet
Description: Participants will receive various doses of the MR Prototype Mini-Tablet orally.
Study NCT06534567 — intervention group
Intervention type: OTHER
Intervention: Mediterranean Diet
Description: Mediterranean diet adherence
Study NCT06534567 — intervention group
Intervention type: OTHER
Intervention: Physical activity
Description: Physical activity level
Study NCT05664750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human tetanus immunoglobulin (HTIG)
Description: Dosage Form: Injection, solution~Route of administration: IM gluteal injection
Study NCT05402761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-guided BBTi group
Description: On the arrival for the baseline appointment, participants will receive workbooks which include an outline and content of BBTi. In the end of week 1 and 3, nurse interventionist will meet participants to review their sleep diary data and negotiate their bedtime and wake-time schedule. During the weeks 2 and 4, participants will receive planned follow-up phone calls to assess their adherence and review progress and challenges.
Study NCT05402761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile-delivered BBTi group
Description: They will use the app in conjunction with the standard BBTi procedures provided by the app, such as stimulus control, sleep restriction and audio-guided relaxation techniques (suggest to use before bedtime).
Study NCT05313620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib 5 MG/day per clinical practice
Study NCT05313620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab Adalimumab y Golimumab
Description: Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice or adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus) per clinical practice or or golimumab (subcutaneus 50 mg milligram(s)-subcutaneus) per clinical practice.
Study NCT04946656 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sphenopalatine ganglion block
Description: The sphenopalatine ganglion will be blocked with bupivacaine for this study
Study NCT06361082 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL reconstruction
Description: ACL reconstruction
Study NCT04855708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual visit
Description: Patients randomized to this group will have a virtual 2-week post-operative visit
Study NCT06313762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pico G2 Virtual Reality Glasses (Pico Interactive Inc), together with an Android AOYODKG tablet
Description: They will experience in first person the two and a half minute graphic adventure, called Leia\&amp;amp;amp;amp;#39;s World, during the administration of the vaccines.
Study NCT06313762 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Distractors
Description: The control group participants will receive traditional distractors, such as being held by the parent or guardian who accompanies them to the appointment, receiving stickers at the end of the appointment, or receiving rewards that the parent or guardian has prepared from home, during the administration of the vaccines.
Study NCT06313762 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Triple Viral + Varicella Vaccine at 3 years of age
Description: Administration of vaccines in 3-year-old children, as appropriate according to the vaccination schedule
Study NCT06313762 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Triple Viral + Varicella Vaccine at 3 years of age
Description: Administration of vaccines in 3-year-old children, as appropriate according to the vaccination schedule
Study NCT06313762 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A + Diphtheria-Tetanus-Pertussis Vaccine at 6 years of age.
Description: Administration of vaccines in 6-year-old children, as appropriate according to the vaccination schedule.
Study NCT06313762 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A + Diphtheria-Tetanus-Pertussis Vaccine at 6 years of age.
Description: Administration of vaccines in 6-year-old children, as appropriate according to the vaccination schedule.
Study NCT06427785 — intervention group
Intervention type: DRUG
Intervention: Remimazolam besylate
Description: Thirty patients underwent elective lower extremity surgery receive spinal anesthesia, and then remimazolam besylate was given intravenously with an induction dose of 3mg/min. When the MOAA/S (Modified Observer's Assessment of Alertness/Sedation) score was ≤1, remimazolam besylate was maintained at 1mg/min for 24min, and finally stopped. Wavelet index, MOAA/S score, blood pressure, heart rate, respiratory rate, and pulse oxygen saturation were continuously monitored during the period.
Study NCT06019650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECMAP
Description: The therapist will deliver 12-week training program comprised of 6 sessions at the participant's home/outpatient clinic depending upon the participants' choice within 3 months. The first two sessions will be offered weekly and then fortnightly.
Study NCT05892354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral immunonutrition
Description: Enteral immunonutrition (Oral Impact®, Nestle), 250ml/ bottle, 2 bottles per day, from 5 days before radiotherapy to the end of radiotherapy.
Study NCT05892354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard enteral nutrition
Description: Isocaloric standard enteral nutrition formula (ENSURE®)， 250 mL per administration, 3 times per day. Preparation of the 250 mL dose involves adding 200 mL of potable water to a cup and slowly stirring in 52.7 g of ENSURE powder (approximately 6 scoops).
Study NCT05497284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTP001
Description: LTP001 will be administered once daily in the morning
Study NCT05497284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to LTP001 will be administered once daily in the morning
Study NCT05497284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (SoC)
Description: nintedanib, pirfenidone, or neither
Study NCT04378244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DeltaRex-G
Description: This is an open label, dose-seeking phase 1/2 study using escalating doses of DeltaRex-G given intravenously for 7 days in a hospital setting.~The study will employ the standard Cohort of Three design (Storer, 1989). Three patients are treated at each dose level with expansion to six patients per cohort if DLT is observed in one of the three initially-enrolled patients at each dose level. If no DLT occurs in 3 patients, escalation to the next dose level will be permitted. The maximum tolerated dose is defined as the highest safely tolerated dose, where not more than one patient experienced DLT, with the next higher dose level having at least two patients who experienced DLT. No intra-patient dose escalation will take place. Patients who do not complete the 7-day treatment will be replaced.
Study NCT04855708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Office visit
Description: Patients randomized to this group will have a in-person 2-week post-operative visit
Study NCT05802238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Description: 1 gram of TXA in 10mg single-dose ampule (100mg/mL) administered 10 minutes prior to surgery
Study NCT05802238 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: control group will receive 10 mL of normal saline infused intravenously at 1 mL/min.
Study NCT06393465 — intervention group
Intervention type: DRUG
Intervention: Tafamidis
Description: 61 milligrams under real world conditions
Study NCT06383975 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed field ablation with posterior wall isolation
Description: Extended pulmonary vein isolation including posterior wall isolation using pulsed field ablation
Study NCT06383975 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation and vein of Marshall ethanolization
Description: Radiofrequency pulmonary vein re-isolation (when necessary), vein of Marshall ethanol infusion with roof and mitral lines
Study NCT06568692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCS6422 and capecitabine
Description: PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer.
Study NCT06568692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Commercially available capecitabine is a commonly used oral fluoropyrimidine.
Study NCT06670820 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS
Description: iTBS targeting the left dorsolateral prefrontal cortex (DLPFC) per session, total10 sessions
Study NCT06670820 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: sham iTBS targeting the left dorsolateral prefrontal cortex (DLPFC) per session, total 10 sessions
Study NCT06670898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] NS-580
Description: Oral suspension
Study NCT06669078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nal-lRl+Oxaliplain+5- FU +PD 1
Description: Nal-lRl+Oxaliplatin+5- FU +PD-1, these drugs are given on d1, d15, 28 days as one cycle, SBRT is performed during the third and fourth cycle.
Study NCT06669078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nal-lRl+Oxaliplain+5- FU
Description: Nal-lRl+Oxaliplatin+5- FU, these drugs are given on d1, d15, 28 days as one cycle.
Study NCT06451068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral retina robotically aligned optical coherence tomography (OCT) system
Description: To visualize the full 360° of the retinal periphery (from equator to the more anterior ora serrata), investigators developed and redesigned a conical mirror contact lens and our non-contact robotically aligning platform to deliver OCT to the peripheral retina. The peripheral retina robotically aligned OCT (PR-RAOCT) system is built around a 6-axis cooperative robot (UR5e, Universal Robots), using our previously developed RAOCT control software.
Study NCT06451068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Likert Scales
Description: Survey evaluating relative comfort with each type of peripheral exam (scleral depression vs. PR-RAOCT). Participants will rate 3 items on a 1 (non) to 5 (maximum) Likert scale: overall discomfort, physical pain, and photophobia for each exam.
Study NCT06240312 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Images of eye at 2 eye pressures
Description: subject images of the eye's optic nerve head are studied
Study NCT06300008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetylated fatty acid
Description: use approximately 3 cm long of cream per each side of knee, then apply on the operated knee until completely absorb
Study NCT06300008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: use approximately 3 cm long of cream per each side of knee, then apply on the operated knee until completely absorb
Study NCT06177340 — intervention group
Intervention type: DEVICE
Intervention: visualization of the sacrospinous ligament
Description: visualization of the sacrospinous ligament by the Nanoscope system during sacrospinofixation
Study NCT05903144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual therapy
Description: manual diaphragmatic release technique combined with breathing exercise
Study NCT05903144 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: breathing exercise and prone position alone
Description: deep breathing exercise and prone position
Study NCT05903144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breathing exercise and prone position alone
Description: deep breathing exercise and prone position
Study NCT05187403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Eye-drops
Study NCT05187403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eye-drops
Study NCT05759234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS248 pieces
Description: The overall safety and tolerability of PI3Kγ inhibitor monotherapy for solid tumors is good, and it has shown preliminary clinical benefits. The safety of PI3Kγ inhibitor combined with immune checkpoint inhibitor is good, and the efficacy of single drug is significantly improved. Based on the evaluation of the safety and efficacy results of HS248 preclinical and clinical studies of similar PI3Kγ inhibitors, the benefits of this product outweigh the risks for patients with advanced solid tumors who have progressed through standard treatment, have toxicity intolerance, or have no standard treatment regimen. Sufficient to support planned clinical studies.
Study NCT05227508 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BRIZO
Description: A capsule containing 400 mg. SC012 (unique soy extract)
Study NCT05227508 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Comprecel microcrystalline cellulose
Study NCT04246034 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microvascular Breast Reconstruction with Vascularized Lymph Node Transfer
Description: simultaneous free abdominal flaps with VLNT from groin are transferred on a single pedicle for breast reconstruction and postmastectomy lymphedema
Study NCT06338891 — intervention group
Intervention type: OTHER
Intervention: Main questionnaire
Description: Main questionnaire will evaluate the demographic and genetic characteristics, clinical manifestations, and self-perception of sensitivity to wheat or other food and the possible relationship between the intake of wheat or other foods and the flare-ups of the disease in FMF patients
Study NCT06338891 — intervention group
Intervention type: OTHER
Intervention: Secondary questionnaire
Description: Secondary questionnaire will investigate the possible appearance of gastrointestinal and extraintestinal symptoms linked to the ingestion of gluten/wheat, which are not identifiable, by the patient, as FMF flare-ups, but might be compatible with a NCGS/NCWS diagnosis
Study NCT05531045 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT
Description: FDG PET/CT assessed after 2 cycles of chemotherapy with PERCIST criteria
Study NCT05032703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm ergometer
Description: The conventional physical therapy program included three sets of exercises as follows:~Flexibility exercises to restore joint mobility of soft tissues. Static and dynamic balance exercise. Functional walking exercises.
Study NCT06535594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Description: Laser acupuncture therapy will be performed five times a week for 4 weeks using laser beam. The acupoints on the ear that will be treated with laser acupuncture therapy are Zhouliao (LI12), Chize (LU5), Quchi (LI11), Shousanli (LI10) and Ashi.
Study NCT06535594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: Physical therapy method involved six elbow joint exercises. Patients performed the six exercises sequentially under guidance, each exercise performed five times, three times a day, gradually increasing weight until the movement was effective but below the pain threshold.
Study NCT05942313 — intervention group
Intervention type: DRUG
Intervention: Buprenorphine/ Methadone exposure
Description: Validate candidate genes- and prenatal opioid exposure- related maternal relapse and NOWS outcome associations in pregnant women and their newborns.
Study NCT06104215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BGT007H Injection
Description: BGT007H injection (d0) were infused intravenously once, and the dose group was 2.0× 10\^8 cells,5.0 ×10\^8 cells, 1.0× 10\^9 cells,3.0 × 10\^9 cells,6.0 ×10\^9 cells.
Study NCT04993924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix Acetate, Ganerelix Acetate
Description: 3-6 days of 0.25 mg starting on day 2-3 of the menstrual cycle